The in vitro/in vivo correlation of antifungal combination testing is necessary in order to
assess the efficacy of combination regimens. We, therefore, attempted to correlate in vitro …

The interaction of posaconazole and amphotericin B was evaluated in concomitant
treatment of Candida albicans systemic infections in immunocompetent mice by using four …

Previous in vivo studies have characterized the pharmacodynamic characteristics of two
triazole compounds, fluconazole and ravuconazole. These investigations demonstrated that …

Posaconazole is more active than fluconazole against Candida albicans in vitro and is
approved for the treatment of oropharyngeal candidiasis but not for that of invasive …

Posaconazole exhibits in-vitro activity against Candida glabrata and Candida krusei.
Epidemiological cut-off values set by the European Committee on Antimicrobial …

We evaluated the effects of sequential therapy with caspofungin (CAS) or amphotericin B
(AMB) followed by posaconazole (POS) against Candida glabrata. The susceptibilities to …

Posaconazole is a recently approved lipophilic triazole antifungal agent that exhibits potent
and broad-spectrum antifungal activity in vitro and in vivo against most Candida spp …

Objectives We evaluated the in vitro activity of posaconazole against nine Candida species
using minimum fungicidal concentration (MFC) measurements and time–kill methods …

There are currently no FDA-approved broth microdilution antifungal susceptibility testing
products or interpretive breakpoints for susceptibility testing of the new triazole …

It is generally accepted that only the unbound fraction of a drug is pharmacologically active.
Posaconazole is an antifungal agent with a protein binding of 98 to 99%. Taking into …